

Table 1. Baseline demographics and clinical characteristics of patients with Crohn's disease (n=104) treated with vedolizumab and followed up for 52 weeks	
Median age at treatment initiation yr. (IQR)	41 (31-52)
Sex; male no. (%)	51 (49)
Median disease duration yr. (IQR)	9 (4-20)
Current smoker no. (%)	12 (11.5)
Location–no. (%)	
Ileal (L1)	17 (16.3)
Colonic (L2)	30 (28.8)
Ileocolonic (L3)	56 (53.8)
Upper Gastrointestinal (L4) only	1 (1)
Behaviour–no. (%)	
Non-stricturing, non-penetrating (B1)	54 (51.9)
Stricturing (B2)	36 (34.6)
Penetrating (B3)	14 (13.5)
Perianal disease–no. (%)	25 (24)
Previous anti-TNF therapy – no. (%)	95 (91.3)
Reason for termination of last anti-TNF no. (%)	
Primary non response	19 (20.0)
Secondary loss of response/Intolerance	63 (66.3)
Other reasons	9 (9.5)
Unknown	4 (4.2)